OCRH ( DrugBank: - )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 75 | Cushing disease | 2 |
| 232 | Carney complex | 1 |
75. Cushing disease
Clinical trials : 205 / Drugs : 176 - (DrugBank : 45) / Drug target genes : 61 - Drug target pathways : 127
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00001452 (ClinicalTrials.gov) | December 14, 1995 | 3/11/1999 | Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex | Definition of the Genotype and Clinical Phenotype of Primary Pigmented Nodular Adrenocortical Disease (PPNAD), Carney Complex, Peutz-Jeghers Syndrome and Related Conditions | Cushing's Syndrome;Pituitary Adenoma;Carney Complex;Primary Pigmented Nodular Adrenocortical Disease;Peutz-Jeghers Syndrome | Drug: oCRH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | NULL | Completed | 3 Years | 70 Years | All | 1387 | United States | |
| 2 | NCT00001180 (ClinicalTrials.gov) | March 1982 | 3/11/1999 | Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency | Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency | Adrenal Gland Hyperfunction;Adrenal Gland Hypofunction;Cushing's Syndrome;Healthy | Drug: Ovine Corticotropin-Releasing Hormone (oCRH) | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | NULL | Completed | N/A | N/A | Both | 2250 | N/A | United States |
232. Carney complex
Clinical trials : 2 / Drugs : 2 - (DrugBank : 1) / Drug target gene : 1 - Drug target pathways : 29
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00001452 (ClinicalTrials.gov) | December 14, 1995 | 3/11/1999 | Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex | Definition of the Genotype and Clinical Phenotype of Primary Pigmented Nodular Adrenocortical Disease (PPNAD), Carney Complex, Peutz-Jeghers Syndrome and Related Conditions | Cushing's Syndrome;Pituitary Adenoma;Carney Complex;Primary Pigmented Nodular Adrenocortical Disease;Peutz-Jeghers Syndrome | Drug: oCRH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | NULL | Completed | 3 Years | 70 Years | All | 1387 | United States |